BMYHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $68 — +6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (65): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +6.5% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | Argus Research | Upgrade | Buy | $75 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $66 → $70 |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Neutral | $54 → $59 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $72 → $75 |
| 31 July 2026 | JP Morgan | Maintains | Overweight | $67 → $73 |
| 31 July 2026 | RBC Capital | Maintains | Sector Perform | $60 → $64 |
| 31 July 2026 | Truist Securities | Reiterates | Buy | $65 → $70 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $60 → $65 |
| 10 July 2026 | B of A Securities | Maintains | Buy | $67 → $66 |
| 10 July 2026 | B of A Securities | Maintains | Buy | — |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | $54 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 9 Apr 2026 | B of A Securities | Maintains | Buy | — |
| 8 Apr 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 8 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 17 Mar 2026 | HSBC | Maintains | Hold | — |
| 25 Feb 2026 | RBC Capital | Initiates | Sector Perform | — |
| 23 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2026 | Barclays | Initiates | Overweight | — |
| 6 Feb 2026 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMY appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 46% of US stocks
Cheaper than 19% of US stocks
Cheaper than 43% of US stocks
Higher than 41% of US stocks
Higher than 88% of US stocks
Higher than 84% of US stocks
Higher than 89% of US stocks
Higher than 82% of US stocks
Higher than 92% of US stocks
Higher than 93% of US stocks
Higher than 77% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bristol Myers Squibb received FDA accelerated approval for Zenbexus, the first CELMoD therapy, after data showed it doubles MRD-negative complete response rates.
Why it matters — This approval marks a milestone for BMY's CELMoD platform, potentially supporting the company's broader growth strategy with a novel therapy class.
The Motley Fool published a comparison of AbbVie and Bristol-Myers Squibb, noting that AbbVie's revenue growth is driven by its immunology and aesthetics products, while Bristol-Myers Squibb maintains high net margins and trades at a valuation discount relative to its peer.
Why it matters — The article highlights Bristol-Myers Squibb's strong net margins and discounted valuation, which are key factors for investors assessing the company's competitive position in the healthcare sector going into 2026.
Rumors surfaced earlier this month that AstraZeneca and Bristol Myers Squibb could pursue a merger, a combination that on paper would create an oncology-focused big pharma powerhouse valued at around $400 billion. Investors reacted negatively to the reports.
Why it matters — BMY watchers would care because merger speculation could affect sentiment and strategic positioning for the company amid reported investor pushback.
The U.S. FDA granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS, used in combination with daratumumab, hyaluronidase-fihj and dexamethasone (ZDd) for patients with multiple myeloma as early as first relapse.
Why it matters — A BMY watcher would care because the approval adds a new, first-of-its-kind CELMoD therapy to the company's oncology portfolio for treating multiple myeloma.
The US FDA approved Bristol Myers Squibb's combination treatment for a rare form of blood cancer in patients whose illness had relapsed or not responded to other treatments.
Why it matters — This approval expands BMY's oncology portfolio and provides a new treatment option for patients with limited alternatives.
The 28 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $68, with estimates ranging from $40 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Bristol Myers Squibb Co., 10 rate it a Buy, 17 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 99 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Bristol Myers Squibb Co. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +6.5% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 99 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $80 over the next 12 months.
Bristol Myers Squibb Co. returned +39.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, and commercializing medicines for serious diseases. Bristol-Myers Squibb Company’s portfolio spans oncology, hematology, immunology, cardiovascular disease, and neuroscience, with products that include small-molecule drugs, biologics, and CAR-T cell therapies.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Can BMY's First CELMoD Approval Support Its Growth Strategy?". Bristol Myers Squibb received FDA accelerated approval for Zenbexus, the first CELMoD therapy, after data showed it doubles MRD-negative complete response rates.
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, and commercializing medicines for serious diseases. Bristol-Myers Squibb Company’s portfolio spans oncology, hematology, immunology, cardiovascular disease, and neuroscience, with products that include small-molecule drugs, biologics, and CAR-T cell therapies. The company serves patients and healthcare providers worldwide through branded therapies and specialty medicines used in complex treatment settings. Bristol-Myers Squibb Company also supports ongoing research and development across multiple therapeutic areas, combining scientific expertise with large-scale manufacturing and distribution capabilities. Headquartered in Princeton, New Jersey, and founded in 1933, Bristol-Myers Squibb Company remains a major participant in the global pharmaceutical market, known for advancing treatments aimed at addressing high-need medical conditions.
CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com